Torflash MD

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only

Abbreviated Prescribing information for Torflash MD (Cholecalciferol Granular Powder) [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Cholecalciferol is the naturally occurring form of vitamin D.

INDICATION: It is used in the treatment and prevention of vitamin D deficiency states and hypocalcaemia in disorders such as hypoparathyroidism and secondary hyperparathyroidism.

DOSAGE AND ADMINISTRATION: Torflash is usually given orally in dose of 400-800 units daily for adults. In certain conditions 40,000 -2, 00,000 units can also be administered.

CONTRAINDICATION: It is contra-indicated in patients having hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D and hypervitaminosis D and hypersensitivity to the drug or other component of the formulation.

WARNINGS & PRECAUTIONS: It should be keep out of the reach of children. Plasma phosphate concentrations should be controlled during vitamin D treatment. It is advisable to monitor plasma calcium concentration at regular intervals during treatment.

DRUG INTERACTION: It may interact when given with thiazide diuretics, calcium, or phosphate. Antiepileptic may increase vitamin D requirements. Rifampicin and isoniazid, corticosteroids may interact with effect of vitamin D. Ketoconazole should be taken with caution. Mineral oil interferes with the absorption of vitamin D preparations.

ADVERSE REACTIONS: Hyperphosphataemia, hypercalcaemia, hypercalciuria, ectopic calcification, renal and cardiovascular damage, impairment of renal function with polyuria, nocturia, polydipsia, reversible azotemia, hypertension, mental retardation, calcification of the soft tissues, bone demineralization (osteoporosis), nausea, anorexia, constipation, anemia, weight loss and mild acidosis.

MARKETED BY:

TORRENT PHARMACEUTICALS LTD.
Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/TORFLASH MD/MAR 2015/01/AbPI

(Additional information is available on request)